Table 4.
Most common tumor somatic variants and their association with patient outcomes in advanced, unresectable BTC
| Mutation | Frequency(%) | HR | Median OS (Mos.) | FDR |
|---|---|---|---|---|
| ARID1A(+) | 11(12.79%) | 1.557 | 11.42 | 0.3120 |
| ARID1A(−) | 75(87.21%) | . | 18.60 | . |
| BRAF(+) | 12(13.95%) | 0.576 | Not reached | 0.3120 |
| BRAF(−) | 74(86.05%) | . | 12.32 | . |
| CDKN2A_B(+) | 28(32.56%) | 0.602 | Not reached | 0.3120 |
| CDKN2A_B(−) | 58(67.44%) | . | 12.32 | . |
| FGFR2(+) | 11(12.79%) | 0.116 | 25.76 | 0.0520 |
| FGFR2(−) | 75(87.21%) | . | 12.09 | . |
| IDH1(+) | 10(11.63%) | 0.556 | Not reached | 0.3120 |
| IDH1(−) | 76(88.37%) | . | 16.82 | . |
| KRAS(+) | 21(24.42%) | 1.677 | 9.56 | 0.3120 |
| KRAS(−) | 65(75.58%) | . | 21.85 | . |
| PBRM1(+) | 10(11.63%) | 0.898 | 12.32 | 0.8201 |
| PBRM1(−) | 76(88.37%) | . | 16.82 | . |
| PIK3CA(+) | 13(15.12%) | 0.531 | 42.58 | 0.3120 |
| PIK3CA(−) | 73(84.88%) | . | 14.46 | . |
| SMAD4(+) | 9(10.47%) | 2.038 | 8.28 | 0.3120 |
| SMAD4(−) | 77(89.53%) | . | 18.60 | . |
| TP53(+) | 25(29.07%) | 3.154 | 8.44 | 0.0018 |
| TP53(−) | 61(70.93%) | . | 25.36 | . |
Genes with an incidence > 10% of all patients with stage III or IV BTC were assessed for their association with overall survival. (+) indicates the presence of a mutation in the listed gene.